Core Insights - Simon and Humana have launched the Humana Walking Club to promote health and community engagement at 21 Simon centers across the U.S. [1][2] - The initiative aims to encourage physical activity through organized mall walks and challenges, with no participation cost, and events scheduled monthly before mall opening hours [2][4] - The program will run from August to December 2025, focusing on older adults and utilizing customized spaces and digital assets for enhanced engagement [3][4] Company Overview - Simon is a real estate investment trust (REIT) that owns premier shopping, dining, entertainment, and mixed-use destinations, recognized as an S&P 100 company [5] - Simon's properties generate billions in annual sales and serve as community gathering places for millions of people daily [5] - Humana is dedicated to prioritizing health through insurance and healthcare services, aiming to improve the quality of life for various demographics, including those with Medicare and Medicaid [6]

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). CONTACT: CLASS PERIOD: December 12, 2024 to June 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors be ...

No one knows what tomorrow holds. At least with some companies, though, it's easier to predict better prospects in the next year than they're experiencing now. I can think of one great example off the top of my head. Meet the 3.4% yield dividend stock that could soar in 2026: UnitedHealth Group (UNH 3.96%). A blue chip stock that has a case of the blues You could honestly say that UnitedHealth Group is a blue chip stock that has a case of the blues. The healthcare giant's Change Healthcare subsidiary was th ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of the 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states, representing 72% of its marketplace membership, was lower than expected [3]. - The company adjusted its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

Group 1 - A New York state man, Shane Daley, was arrested for allegedly leaving threatening voicemails for Paulette Thompson, the widow of UnitedHealthcare CEO Brian Thompson, following his murder [1][5] - The voicemails contained profanity and threats, expressing anger towards the healthcare industry and accusing Brian Thompson of exploiting poor Americans [2][5] - Brian Thompson was killed on December 4, 2023, as he was about to attend an investor conference, and Luigi Mangione has been charged with his murder [3][5] Group 2 - The FBI linked Daley to the threatening messages through his personal cellphone number, which was recorded during the calls to Paulette's work line [6] - Daley initially denied making the threatening calls when confronted by law enforcement, but his voice was recognized by an FBI agent [7]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Humana Inc. and DrFirst have launched a program aimed at improving medication therapy for patients with chronic conditions, particularly focusing on increasing statin therapy usage among eligible Medicare patients [1][2]. Group 1: Program Details - The program is designed to close care gaps for patients with chronic health conditions such as diabetes and cardiovascular disease [1]. - It utilizes the DrFirst prescription orchestration platform to facilitate timely prescription recommendations for high-risk patients, allowing healthcare providers to easily approve or decline these recommendations [2][3]. - The initiative aligns with quality metrics set by the Centers for Medicare & Medicaid Services (CMS) [1]. Group 2: Technology and Collaboration - The DrFirst platform enhances real-time interoperability among healthcare stakeholders, including providers, pharmacies, and payers, to improve patient outcomes [3][4]. - This partnership builds on a decade of collaboration between Humana and DrFirst, which includes the introduction of the first real-time prescription benefit tool in 2015 [5]. Group 3: Company Backgrounds - Humana Inc. focuses on health and well-being, providing services to various demographics, including Medicare and Medicaid recipients [6]. - DrFirst has been a pioneer in healthcare IT for 25 years, offering intelligent medication management solutions that enhance prescription access and adherence [7].

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]

Financial Performance & Growth - Clover Health anticipates insurance revenue of $1.8 billion to $1.875 billion for full year 2025[50] - The company projects Adjusted EBITDA between $50 million and $70 million for full year 2025[9, 50] - Clover Health expects a 32% year-over-year increase in Medicare Advantage (MA) membership in 2025[9, 44] - Clover Health's Insurance Benefits Expense Ratio (BER) for the first half of 2025 was 87.3%[24] Clover Assistant & Clinical Outcomes - Clover Assistant (CA) is associated with earlier diagnosis of Chronic Kidney Disease (CKD) by approximately 18 months on average[18] - Clover Assistant is associated with 15% lower all-cause hospitalizations and 18% lower 30-day readmissions for members with Chronic Obstructive Pulmonary Disease (COPD)[18, 20] - Clover Health achieved a 4.94 out of 5 Stars on HEDIS measures for Star Rating year 2025, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide[18] Strategic Initiatives - Clover Health is focused on a ~$500 billion market with over 35 million seniors enrolled in Medicare Advantage[8] - Clover Health's Counterpart Health subsidiary aims to expand the company's care model to more plans and providers[8] - Approximately 97% of Clover Health's membership is enrolled in PPO plans[8, 49]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score focuses on a company's financial health and future growth potential [4] - Momentum Score capitalizes on existing trends in stock prices and earnings [5] - VGM Score combines the strengths of all three Style Scores to identify the most attractive investment opportunities [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Example: Humana Inc. (HUM) - Humana Inc. is a major health care plan provider in the U.S., offering various health insurance products [11] - Currently rated 3 (Hold) by Zacks, Humana has a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [12] - Recent analyst revisions have increased Humana's earnings estimate for fiscal 2025, with a consensus estimate of $16.93 per share and an average earnings surprise of +9.6% [12] - Given its solid Zacks Rank and favorable Style Scores, Humana is recommended for investors' consideration [13]